Y Intercept Hong Kong Ltd Reduces Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Y Intercept Hong Kong Ltd trimmed its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 17.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,623 shares of the biotechnology company’s stock after selling 14,500 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth $516,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $46,000. R Squared Ltd purchased a new position in BioCryst Pharmaceuticals in the fourth quarter valued at about $48,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,322 shares during the last quarter. KBC Group NV boosted its stake in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after acquiring an additional 4,537 shares during the last quarter. Finally, Quantinno Capital Management LP purchased a new position in BioCryst Pharmaceuticals in the third quarter valued at about $82,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 1.7 %

BioCryst Pharmaceuticals stock opened at $8.61 on Friday. The firm’s 50 day simple moving average is $8.11 and its 200 day simple moving average is $7.86. The firm has a market capitalization of $1.78 billion, a PE ratio of -14.11 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 earnings per share. Research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BCRX. Evercore ISI boosted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Barclays boosted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Needham & Company LLC boosted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.